HARROW, INC. — fact timeline

HARROW, INC. shareholders approved Ratification of Auditors at the 2026-06-18 meeting.

“Proposal 3: Ratification of Auditors Stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the voting were: For Against Abstain Broker Non-Vote 28,578,182 1,249,248 3,543”

HARROW, INC. shareholders approved To approve on an advisory basis, the compensation of the Company’s named executive officers at the 2026-06-18 meeting.

“Proposal 2: To approve on an advisory basis, the compensation of the Company’s named executive officers Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of the voting were: For Against Abstain Broker Non-Vote 18,065,856 2,395,240 502,679 8,867,198”

HARROW, INC. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1: Election of Directors Stockholders voted to elect to the Board of Directors the four (4) director nominees named in the Company’s proxy statement to serve until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified. The results of the voting were: Directors For Withheld Broker Non-Vote Mark L. Baum 18,733,392 2,230,383 8,867,198 Adrienne L. Graves 19,375,636 1,588,139 8,867,198 Lauren P. Silvernail 19,423,429 1,540,346 8,867,198 Perry J. Sternberg 19,427,617 1,536,158 8,867,198”

HARROW, INC. reported quarter ended March 31, 2026 results: revenue $44,203,000, net income Net loss $(27,602,000), EPS $(0.74). Guidance reaffirmed.

“Total revenues $ 44,203,000 $ 47,831,000 Gross margin 61 % 68 % Net loss (27,602,000 ) (17,780,000 ) Adjusted EBITDA (1) (12,659,000 ) (1,985,000 ) Net loss per share, basic and diluted (0.74 ) (0.50 )”

HARROW, INC. entered into First Supplemental Indenture with U.S. Bank Trust Company, National Association valued at 50,000,000 (effective 2026-03-27).

“On March 27, 2026, the Company, the subsidiary guarantors named therein (the “Guarantors”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), entered into a First Supplemental Indenture (the “First Supplemental Indenture”) to the Indenture, dated September 12, 2025 (the “Base Indenture” and, together with the First Supplemental Indenture, the “Indenture”) pursuant to which the Company issued the New Notes.”

HARROW, INC. entered into Purchase Agreement with BTIG, LLC valued at 50,000,000 (effective 2026-03-24).

“On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”).”

HARROW, INC. incurred senior notes of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 with BTIG, LLC, as representative of the several initial purchasers at 8.625% maturing 2030.

“On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”).”

HARROW, INC. completed an acquisition involving Melt Pharmaceuticals, Inc. for approximately $4.3 million in cash (closed 2025-11-17).

“in the Company’s Current Report on Form 8-K filed on September 26, 2025, which description is incorporated herein by reference. At closing, the Company paid approximately $4.3 million in cash as initial consideration for the remaining equity interests of Melt. The contingent regulatory and commercial milestone payments described in the Company’s September 26,”

HARROW, INC. incurred revolving credit of $40,000,000 initial principal amount, together with an uncommitted incremental revolving line of credit of up to $20,000 with Fifth Third Bank, National Association at floating rate equal to, at the Company’s option, either (i) a base rate plus a m maturing September 26, 2030 or, if earlier, the date that is 91 days prior to the earliest maturity date of the Company’s 8.625% senior notes due 2030.

“On September 26, 2025, Harrow, Inc., (the " Company "), and subsidiaries of the Company as guarantors (" Subsidiary Guarantors ") entered into a Credit Agreement (the " New Credit Agreement ") with Fifth Third Bank, National Association, as administrative agent for itself and the other lenders, the letter of credit issuer, the swing line lender, the sole lead arranger and the sole bookrunner (" Fifth Third ") providing for a senior secured revolving credit facility in the initial principal amount of $40,000,000, together with an uncommitted incremental revolving line of credit in the principal amount of up to $20,000,000.”

HARROW, INC. engaged Deloitte & Touche LLP as its auditor.

“On September 17, 2025, the Audit Committee approved the appointment of Deloitte & Touche LLP (“ Deloitte ”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2025.”

HARROW, INC. dismissed Crowe LLP as its auditor.

“On September 17, 2025, Harrow, Inc. (the “ Company ”), through action of the Audit Committee (the “ Audit Committee ”) of the Company’s Board of Directors, dismissed Crowe LLP (“ Crowe ”) as the Company’s independent registered public accounting firm, effective immediately.”

HARROW, INC. incurred senior notes of $250.0 million aggregate principal amount with U.S. Bank Trust Company, National Association, as trustee at 8.625% per annum maturing September 15, 2030.

“Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of $250.0 million aggregate principal amount of 8.625% senior notes due 2030 (the “2030 Notes”). The terms of the 2030 Notes sold pursuant to the Purchase Agreement are summarized below. The”

HARROW, INC.: Amended and restated bylaws to update officer roles, titles, and governance practices (effective 2025-08-21).

“On August 21, 2025, the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company (the “Amended Bylaws”), effective immediately.”

Marty A. Makary resigned as Director at HARROW, INC..

“On January 17, 2025, Marty A. Makary informed the Board of Directors (the “Board”) of Harrow, Inc. (the “Company”) that he is resigning as a member of the Company’s Board, with such resignation to be effective as of 11:59 p.m. ET on January 19, 2025.”

HARROW, INC. reported the first quarter ended March 31, 2024 results: revenue $34,587,000, net income (13,565,000), EPS (0.38). Guidance reaffirmed.

“First quarter 2024 figures of merit: For the Three Months Ended March 31, 2024 2023 Net revenues $ 34,587,000 $ 26,103,000 Gross margin 69 % 68 % Core gross margin (1) 76 % 76 % Net loss (13,565,000 ) (6,643,000 ) Core net loss (1) (9,789,000 ) (1,042,000 ) Adjusted EBITDA (1) 227,000 5,342,000 Basic and diluted net loss per share (0.38 ) (0.22 )”

HARROW, INC. reported the year and quarter ended December 31, 2023 results: revenue $130,193,000, net income $(24,411,000), EPS $(0.75).

“Form 8-K. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Harrow Announces Fourth Quarter and Year-End 2023 Financial Results Full-Year 2023 Highlights: ● Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. ● GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. ● Adjusted EBITDA of $28.1”

Lauren P. Silvernail was elected as Director at HARROW, INC..

“On January 26, 2024 (the “Effective Date”), the board of directors (the “Board”) of Harrow, Inc. (the “Company”), following the recommendation of the Nomination and Corporate Governance Committee of the Board, expanded the size of the Board from four members to six and elected Adrienne L. Graves, Ph.D. and Lauren P. Silvernail to serve as members of the Board, effective immediately.”

Adrienne L. Graves was elected as Director at HARROW, INC..

“On January 26, 2024 (the “Effective Date”), the board of directors (the “Board”) of Harrow, Inc. (the “Company”), following the recommendation of the Nomination and Corporate Governance Committee of the Board, expanded the size of the Board from four members to six and elected Adrienne L. Graves, Ph.D. and Lauren P. Silvernail to serve as members of the Board, effective immediately.”

HARROW, INC.: Amendments to the Code of Business Conduct and Ethics to update corporate name and clarify obligations regarding political activities (effective 2023-12-28).

“Effective December 28, 2023, the Board of Directors of the Company approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) upon the recommendation of the Nomination and Corporate Governance Committee of the Board.”

John P. Saharek was appointed as President and Chief Executive Officer of the Company's ImprimisRx division at HARROW, INC..

“Effective January 2, 2024, Harrow, Inc. (the “Company”) appointed John P. Saharek as the President and Chief Executive Officer of the Company’s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.”

HARROW, INC. updated its the third quarter and nine months ended September 30, 2023 guidance (reaffirmed).

“On November 13, 2023, Harrow, Inc. (the "Company") issued a press release and a letter to stockholders announcing its financial results for the period ended September 30, 2023 and an update on recent corporate events.”

R. Lawrence Van Horn resigned as Director at HARROW, INC..

“On November 3, 2023, R. Lawrence Van Horn informed the Board of Directors (the “Board”) of Harrow, Inc. (the “Company”) that he is resigning as a member of the Company’s Board, with such resignation to be effective immediately.”

HARROW, INC.: Amended and restated bylaws solely to reflect the name change (effective 2023-09-29).

“On the effective date of the Name Change, the Company also amended and restated its bylaws (the “ Amended and Restated Bylaws ”) solely to reflect the Name Change.”

HARROW, INC.: Changed corporate name from Harrow Health, Inc. to Harrow, Inc. via certificate of amendment to the amended and restated certificate of incorporation (effective 2023-09-29).

“Effective as of September 29, 2023, Harrow Health, Inc. (the “ Company ”) changed its corporate name to Harrow, Inc. (the “ Name Change ”) pursuant to a certificate of amendment to the Company’s amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware.”

HARROW, INC. reported financial results for the second quarter and six months ended June 30, 2023.

“On August 9, 2023, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended June 30, 2023 and an update on recent corporate events.”

HARROW, INC. entered into Underwriting Agreement with B. Riley Securities, Inc., as representative of the several underwriters named therein valued at $69.0 million (effective 2023-07-18).

“On July 18, 2023, Harrow Health, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with B. Riley Securities, Inc., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), related to a public offering of shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at an offering price of $17.75 per share (the “ Offering ”).”

HARROW, INC. reported second quarter 2023 results: revenue in excess of $31.0 million.

“Management expects the Company to record over $31,000,000 of total revenues and over $9,300,000 of Adjusted EBITDA (a non-GAAP measure) for the three-month period ended June 30, 2023.”

HARROW, INC. amended Oaktree Amendment with Oaktree Fund Administration, LLC valued at from $100,000,000 to $112,500,000 (effective 2023-07-18).

“On July 18, 2023, Harrow Health, Inc. (the "Company") entered into the First Amendment to Credit Agreement and Guaranty and Consent (the "Oaktree Amendment") to the Credit Agreement and Guaranty (the "Oaktree Loan") originally entered into on March 27, 2023, with the lenders from time to time party thereto and Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, "Oaktree"). Under the Oaktree Amendment, the overall credit facility size was increased from $100,000,000 to $112,500,000, and the Company made other changes related to the Santen Products Acquisition”

HARROW, INC. shareholders approved Advisory approval of compensation of named executive officers at the 2023-06-21 meeting.

“Proposal 3: To approve on an advisory basis, the compensation of the Company's named executive officers. Stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. The results of the voting were: For Against Abstain Broker Non-Vote 19,733,427 849,799 288,213 4,717,947”

HARROW, INC. shareholders approved Ratification of selection of KMJ Corbin and Company, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.

“Proposal 2: Ratification of Auditors Stockholders ratified the selection of KMJ Corbin and Company, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting were: For Against Abstain Broker Non-Vote 25,350,360 210,383 28,643 -”

HARROW, INC. shareholders approved Election of Directors at the 2023-06-21 meeting.

“Proposal 1: Election of Directors Stockholders voted to elect to the Board of Directors the five (5) director nominees named in the Company's proxy statement to serve until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified. The results of the voting were: Directors For Withheld Broker Non-Vote Mark L. Baum 20,771,801 99,638 4,717,947 Martin A. Makary 20,768,755 102,684 4,717,947 Teresa F. Sparks 12,184,918 8,686,521 4,717,947 Perry J. Sternberg 20,759,602 111,837 4,717,947 R. Lawrence Van Horn 11,916,986 8,954,453 4,717,947”

HARROW, INC. reported first quarter ended March 31, 2023 results: revenue $26,103,000, net income (6,643,000), EPS (0.22). Guidance reaffirmed.

“We are excited to kick off 2023 with a strong first quarter that demonstrates the continuing successful execution of our strategic plan aimed at elevating Harrow into a leading position among top-tier U.S. eyecare pharmaceutical companies," said Mark L. Baum, CEO of Harrow. "We are pleased that our Harrow team delivered record revenues of $26.1 million, a 28% increase over the fourth quarter of 2022, but, even more important, we see the first quarter of 2023 marking the beginning of a new revenue paradigm for Harrow. Going forward, we expect revenue growth from our branded pharmaceutical products to meaningfully outpace growth from our compounded pharmaceutical products, with revenue from branded products ultimately driving the lion’s share of our future profitability and topline growth. Based on our results to date, we are reaffirming our 2023 guidance of $135 million to $143 million in net revenues and $44 million to $50 million in adjusted EBITDA. “We believe our successful first qu”

HARROW, INC. incurred credit facility of up to $100,000,000 with Oaktree Fund Administration, LLC, as administrative agent for the lenders at SOFR plus 6.5% per annum maturing January 19, 2026.

“On March 27, 2023, Harrow Health, Inc. and certain of its affiliates (together, the “ Company ”) entered into a Credit and Guaranty Agreement (the “ Oaktree Loan ”) with Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, “ Oaktree ”), providing for a loan to the Company with a principal amount of up to $100,000,000.”

HARROW, INC. terminated B. Riley Loan with B. Riley Commercial Capital, LLC (effective 2022-12-14).

“the Company drew a principal amount of $65,000,000 from the Oaktree Loan and used the net proceeds to repay all amounts owed by the Company pursuant to the Loan and Security Agreement the Company previously entered into with B. Riley Commercial Capital, LLC on December 14, 2022 (the “ B. Riley Loan ”). No remaining amounts are due under the B. Riley Loan”

HARROW, INC. entered into Oaktree Loan with Oaktree Fund Administration, LLC valued at up to $100,000,000 (effective 2023-03-27).

“On March 27, 2023, Harrow Health, Inc. and certain of its affiliates (together, the “ Company ”) entered into a Credit and Guaranty Agreement (the “ Oaktree Loan ”) with Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, “ Oaktree ”), providing for a loan to the Company with a principal amount of up to $100,000,000.”

HARROW, INC. reported the year ended December 31, 2022 results: revenue $88,595,000, net income $(14,086,000), EPS (0.51).

“Fourth quarter and year-end 2022 figures of merit: For the Three Months Ended December 31, For the Years Ended December 31, 2022 2021 2022 2021 Net revenues $ 20,329,000 $ 20,188,000 $ 88,595,000 $ 72,476,000 Gross margin 71 % 75 % 71 % 75 % Core gross margin (1) 71 % 75 % 73 % 75 % Net income (loss) 1,055,000 (7,418,000 ) (14,086,000 ) (18,479,000 ) Core net income (loss) (1) 2,104,000 (3,525,000 ) 1,540,000 (4,353,000 ) Adjusted EBITDA (1)(2) 1,089,000 (1,482,000 ) 13,017,000 11,378,000 Basic and diluted net income (loss) per share 0.04 (0.27 ) (0.51 ) (0.69 )”

HARROW, INC. reported the three months ended December 31, 2022 results: revenue $20,329,000, net income $1,055,000, EPS 0.04.

“Fourth quarter and year-end 2022 figures of merit: For the Three Months Ended December 31, For the Years Ended December 31, 2022 2021 2022 2021 Net revenues $ 20,329,000 $ 20,188,000 $ 88,595,000 $ 72,476,000 Gross margin 71 % 75 % 71 % 75 % Core gross margin (1) 71 % 75 % 73 % 75 % Net income (loss) 1,055,000 (7,418,000 ) (14,086,000 ) (18,479,000 ) Core net income (loss) (1) 2,104,000 (3,525,000 ) 1,540,000 (4,353,000 ) Adjusted EBITDA (1)(2) 1,089,000 (1,482,000 ) 13,017,000 11,378,000 Basic and diluted net income (loss) per share 0.04 (0.27 ) (0.51 ) (0.69 )”

HARROW, INC. completed an acquisition involving Novartis Technology, LLC and Novartis Innovative Therapies AG for $130,000,000 (closed 2023-01-20).

“suspension) 40 mg/ml. Under the terms of the Asset Purchase Agreement between the Company and Novartis (the “Purchase Agreement”), the Company made a one-time payment of $130,000,000 at closing, with up to another $45,000,000 due in a milestone payment related to the commercial availability of Triesence. Pursuant to the Purchase Agreement and various ancillary”

HARROW, INC. incurred credit facility of up to $100,000,000 with B. Riley Commercial Capital, LLC at 10.875% per annum maturing December 14, 2025.

“The Loan Agreement provides for a loan facility of up to $100,000,000 to the Company (the “ Loan ”) with a maturity date of December 14, 2025 (the “ Maturity Date ”), at an interest rate of 10.875% per annum.”

HARROW, INC. incurred senior notes of $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 with B. Riley Securities, Inc. at 11.875% per annum maturing December 31, 2027.

“the Company agreed to sell to the Underwriters $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (the “ Firm Notes ”) plus up to an additional $5,250,000 aggregate principal amount of 11.875% Senior Notes due 2027”

HARROW, INC. entered into Loan and Security Agreement with B. Riley Commercial Capital, LLC valued at a loan facility of up to $100,000,000 to the Company with a maturity date of December 14, 2025, at a (effective 2022-12-14).

“On December 14, 2022 (the “ Effective Date ”), the Company and its material subsidiaries entered into a Loan and Security Agreement (the “ Loan Agreement ”) with B. Riley Commercial Capital, LLC, as Administrative Agent for the Lenders from time to time party thereto. The proceeds of the Loan Agreement are expected to be used to finance the Acquisition (as defined below). The Loan Agreement provides for a loan facility of up to $100,000,000 to the Company (the “ Loan ”) with a maturity date of December 14, 2025 (the “ Maturity Date ”), at an interest rate of 10.875% per annum.”

HARROW, INC. entered into Second Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (effective 2022-12-20).

“On December 20, 2022, the Company entered into a Second Supplemental Indenture (the “ Second Supplemental Indenture ”) to the indenture dated as of April 20, 2021 (the “ Base Indenture ” and, together with the Second Supplemental Indenture, the “ Indenture ”) with U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “ Trustee ”).”

HARROW, INC. entered into Underwriting Agreement with B. Riley Securities, Inc. valued at $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 plus up to an additional $5, (effective 2022-12-15).

“on December 15, 2022, Harrow Health, Inc. (the “ Company ”) entered into an underwriting agreement with B. Riley Securities, Inc., as representative of the several underwriters named therein (collectively the “ Underwriters ”), pursuant to which the Company agreed to sell to the Underwriters $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (the “ Firm Notes ”) plus up to an additional $5,250,000 aggregate principal amount of 11.875% Senior Notes due 2027 pursuant to the option to purchase additional Notes”

HARROW, INC. entered into Notes Underwriting Agreement with B. Riley Securities, Inc., as representative of the several underwriters named therein valued at $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (effective 2022-12-15).

“On December 15, 2022, the Company entered into an underwriting agreement (the “ Notes Underwriting Agreement ”) with B. Riley Securities, Inc., as representative of the several underwriters named therein (the “ Notes Underwriters ”), pursuant to which the Company agreed to sell to the Notes Underwriters $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027”

HARROW, INC. entered into Common Stock Underwriting Agreement with B. Riley Securities, Inc. valued at gross proceeds of $25,000,002 (effective 2022-12-13).

“On December 13, 2022, Harrow Health, Inc. (the “Company”) entered into an underwriting agreement (the “ Common Stock Underwriting Agreement ”) with B. Riley Securities, Inc. (the “ Common Stock Underwriter ”) related to a registered direct offering of shares of the Company’s common stock”

HARROW, INC. entered into Asset Purchase Agreement with Novartis Technology, LLC and Novartis Innovative Therapies AG valued at $130,000,000 (effective 2022-12-13).

“On December 13, 2022, Harrow Health, Inc. along with its wholly-owned subsidiaries, Harrow IP, LLC and Harrow Eye, LLC (individually and together the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Novartis Technology, LLC and Novartis Innovative Therapies AG (together, “Novartis”), pursuant to which the Company agreed to purchase from Novartis the exclusive commercial rights to assets associated with the following ophthalmic products (collectively the “Products”) in the U.S. (the “Acquisition”): ILEVRO® (nepafenac ophthalmic suspension) 0.3%; NEVANAC® (nepafenac ophthalmic suspension) 0.1%; VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%; MAXIDEX® (dexamethasone ophthalmic suspension) 0.1%; and TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/ml.”

HARROW, INC. reported financial results for the third quarter ended September 30, 2022.

“On November 14, 2022, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended September 30, 2022 and an update on recent corporate events.”

Dr. Marty Makary was appointed as Director at HARROW, INC..

“the Board appointed Mr. Perry J. Sternberg and Dr. Marty Makary to fill the vacancies created by Dr. Kammer’s resignation and the expansion of the size of the Board.”

Perry J. Sternberg was appointed as Director at HARROW, INC..

“the Board appointed Mr. Perry J. Sternberg and Dr. Marty Makary to fill the vacancies created by Dr. Kammer’s resignation and the expansion of the size of the Board.”

Dr. Robert J. Kammer resigned as Director at HARROW, INC..

“On March 31, 2022, Dr. Robert J. Kammer informed the Board of Directors (the “Board”) of Harrow Health, Inc. (the “Company”) that he is resigning as a member of the Company’s Board, with such resignation to be effective immediately.”